Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Medicus Pharma › BOKHARI, RAZA disclosed a 19.1% stake in MDCX and may seek to influenc Fund moves
Why it stands out A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Nov 13, 2026
Reporting period Not applicable
Filed with the SEC Nov 17, 2026 activist 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0000950142-26-003112
Data quality Verified: identifiers matched exactly
Around the same time Insider filing
Traded Nov 13 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Nov 13 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Nov 13 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Sep 11, 2026 Company filing · Form 8-K · Agreement ended Ended an important agreement Oct 12, 2026 Company filing · Form 8-K · Shareholder rights, Bylaws or charter Changed the rights of its shareholders, and changed its bylaws, charter or fiscal year Oct 16, 2026 5% stake Melani Kenneth R. reported a passive stake (13G) of 3.6% Oct 20, 2026 Company filing · Form 8-K · Listing notice, Other news Received a notice from its stock exchange, and reported other company news “On October 23, 2026, Medicus Pharma Ltd. (the "Company") received written notice (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance with the $1.00 minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"), and that the matter was…” What came next Nov 16, 2026 Company filing · Form 8-K · Material agreement, Unregistered shares Signed an important agreement, and sold new shares without registering them (and 2 more items) Nov 17, 2026 5% stake BOKHARI, RAZA filed an activist stake (13D) of 19.1% Nov 19, 2026 Company filing · Form 8-K · Listing notice, Reg FD Received a notice from its stock exchange, and shared information with investors (and 1 more item) “As previously disclosed in the Current Report on Form 8-K filed by Medicus Pharma Ltd. (the "Company") with the Securities and Exchange Commission (the "SEC") on May 27, 2026, on May 20, 2026, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that its Market Value of Listed Securities had been below $35 million for the…”